An early clinical study of a CRISPR‑based gene editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in a small cohort, signaling potential for one‑time editing to address lipid disorders. The trial, by CRISPR Therapeutics and collaborators, enrolled 15 patients and reported large lipid declines published in the New England Journal of Medicine and presented at the AHA meeting. Researchers flagged concerns about liver toxicities and emphasized that findings are preliminary given the small sample size. Investigators and clinicians noted the tradeoff between durable lipid control and the long‑term safety and acceptance of permanent gene edits for common cardiometabolic conditions.